ESMO Congress 2026 Spotlights Phase III Immunotherapy Trials in Solid Tumors
The ESMO Congress 2026 features five major phase III clinical trials exploring reduced-frequency checkpoint inhibition, novel radiotherapy combinations, and perioperative treatment strategies across solid tumors. As oncologists gather to evaluate how to balance disease control with treatment burden, trials such as MOIO, UNION, KEYNOTE-975, STARBOARD, and NRG-GY020 aim to refine immunotherapy delivery in metastatic disease, definitive chemoradiotherapy, and early-stage settings, oncodaily.com reported.
MOIO Trial Tests Less Frequent Dosing After Initial Immunotherapy Response
The randomized phase III MOIO trial, registered as NCT05078047, investigates whether patients who respond to standard immunotherapy can safely extend their treatment intervals to every three months without losing efficacy. Gwenaëlle Gravis will present interim analyses from this study during Presidential Symposium III on October 26, 2026. The trial protocols outline a target enrollment of 646 patients with metastatic solid tumors who achieve a complete or partial response after six months of initial checkpoint inhibition. Patients are randomized to maintain their standard dosing schedule or switch to the extended three-month interval, excluding patients with melanoma in complete response.
Using a non-inferiority design, MOIO measures progression-free survival as its primary endpoint. The trial also evaluates overall survival, treatment toxicity, quality of life, cost-effectiveness, and patient anxiety regarding disease recurrence. Because checkpoint inhibitors can maintain biological activity beyond standard dosing windows, the study provides critical data on whether patients can reduce hospital visits without compromising disease control. However, investigators emphasize that reduced frequency does not automatically equate to lower toxicity, making these prospective quality-of-life assessments essential.
UNION Trial Integrates Camrelizumab Into Neoadjuvant Rectal Cancer Therapy
The multicenter phase III UNION trial, designated NCT04928807, evaluates short-course radiotherapy combined with camrelizumab and chemotherapy in locally advanced rectal cancer. Zhen Yu Lin presents these findings during the Proffered Paper session on Gastrointestinal Tumours, Lower Digestive on October 25, 2026. Enrolling 231 patients, UNION compares an experimental regimen of short-course radiotherapy delivering 25 Gy in five fractions followed by two cycles of the PD-1 inhibitor camrelizumab plus CAPOX against a control arm receiving traditional long-course chemoradiotherapy with concurrent capecitabine.
The primary endpoint for UNION is pathological complete response, defined by a blinded independent review committee as the absence of viable tumor cells in the resected primary lesion and regional lymph nodes, or ypT0N0. Because the experimental arm alters both the radiation schedule and adds immunotherapy, the trial evaluates a total therapeutic strategy rather than isolating the individual contribution of camrelizumab. Investigators note that pathological complete response serves as an early indicator of deep tumor regression and does not support omitting standard surgical resection.
Frequently Asked Questions About ESMO 2026 Immunotherapy Trials
What is the primary goal of the MOIO phase III trial?
The MOIO trial investigates whether patients with metastatic solid tumors who respond to six months of standard immunotherapy can safely extend their infusion intervals to every three months without sacrificing progression-free survival.
How many patients does the MOIO trial plan to enroll?
The protocol for MOIO (NCT05078047) specifies a target enrollment of 646 patients who have achieved a partial or complete response after six months of initial checkpoint inhibition therapy.
What treatment regimen does the UNION trial test in rectal cancer?
The UNION trial (NCT04928807) tests short-course radiotherapy delivering 25 Gy in five fractions, followed by camrelizumab combined with capecitabine and oxaliplatin (CAPOX), compared against standard long-course chemoradiotherapy.
These presentations highlight an ongoing clinical shift toward tailoring immunotherapy duration and integrating systemic checkpoint blockade into multimodal curative intent regimens.
Related reading